Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBIO's Cash-to-Debt is ranked higher than
93% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CBIO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 53.26 Max: No Debt
Current: No Debt
0.66
No Debt
Equity-to-Asset 0.98
CBIO's Equity-to-Asset is ranked higher than
99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CBIO: 0.98 )
Ranked among companies with meaningful Equity-to-Asset only.
CBIO' s Equity-to-Asset Range Over the Past 10 Years
Min: -36.68  Med: 0.61 Max: 0.98
Current: 0.98
-36.68
0.98
Interest Coverage No Debt
CBIO's Interest Coverage is ranked higher than
91% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBIO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CBIO' s Interest Coverage Range Over the Past 10 Years
Min: 85.72  Med: No Debt Max: No Debt
Current: No Debt
85.72
No Debt
Piotroski F-Score: 3
Altman Z-Score: 27.04
Beneish M-Score: 99999999.99
WACC vs ROIC
20.53%
-2485.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -3386.45
CBIO's Operating Margin % is ranked lower than
86% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CBIO: -3386.45 )
Ranked among companies with meaningful Operating Margin % only.
CBIO' s Operating Margin % Range Over the Past 10 Years
Min: -5117.29  Med: -287.54 Max: 15.3
Current: -3386.45
-5117.29
15.3
Net Margin % -3063.75
CBIO's Net Margin % is ranked lower than
85% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CBIO: -3063.75 )
Ranked among companies with meaningful Net Margin % only.
CBIO' s Net Margin % Range Over the Past 10 Years
Min: -4246.87  Med: -260.99 Max: 12.72
Current: -3063.75
-4246.87
12.72
ROE % -31.53
CBIO's ROE % is ranked higher than
57% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CBIO: -31.53 )
Ranked among companies with meaningful ROE % only.
CBIO' s ROE % Range Over the Past 10 Years
Min: -108.92  Med: -47.1 Max: 13.55
Current: -31.53
-108.92
13.55
ROA % -28.91
CBIO's ROA % is ranked higher than
55% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CBIO: -28.91 )
Ranked among companies with meaningful ROA % only.
CBIO' s ROA % Range Over the Past 10 Years
Min: -55.57  Med: -13.88 Max: 3.74
Current: -28.91
-55.57
3.74
ROC (Joel Greenblatt) % -1607.41
CBIO's ROC (Joel Greenblatt) % is ranked lower than
64% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CBIO: -1607.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6061.67  Med: -308.1 Max: 268.6
Current: -1607.41
-6061.67
268.6
3-Year Revenue Growth Rate -84.00
CBIO's 3-Year Revenue Growth Rate is ranked lower than
89% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CBIO: -84.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -84  Med: -43.4 Max: 69.3
Current: -84
-84
69.3
3-Year EBITDA Growth Rate 71.50
CBIO's 3-Year EBITDA Growth Rate is ranked higher than
98% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CBIO: 71.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -35.05 Max: 81
Current: 71.5
0
81
3-Year EPS without NRI Growth Rate 69.80
CBIO's 3-Year EPS without NRI Growth Rate is ranked higher than
97% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CBIO: 69.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.4 Max: 92.9
Current: 69.8
0
92.9
» CBIO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CBIO Guru Trades in Q3 2017

Paul Tudor Jones Sold Out
Jim Simons 333,773 sh (-1.74%)
» More
Q4 2017

CBIO Guru Trades in Q4 2017

Jim Simons 355,373 sh (+6.47%)
» More
Q1 2018

CBIO Guru Trades in Q1 2018

George Soros 363,070 sh (New)
Jim Simons 556,373 sh (+56.56%)
» More
Q2 2018

CBIO Guru Trades in Q2 2018

Steven Cohen 600,350 sh (New)
Jim Simons 586,573 sh (+5.43%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2018-06-30 Sold Out 0.17%$9.11 - $28.88 $ 10.21-56%0
George Soros 2018-03-31 New Buy0.17%$14.18 - $35.6 $ 10.21-59%363,070
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:WAR:MAB, SHSE:600556, XKRX:168330, NAS:PIRS, HKSE:08158, NAS:MRUS, NAS:COOL, NAS:PRTK, XPAR:COX, NAS:SBBP, XKRX:200670, NAS:ABUS, XKRX:001630, NAS:CBMG, NAS:CORI, LSE:FARN, NYSE:KDMN, XBRU:CYAD, XKRX:142760, NAS:NK » details
Traded in other countries:HGF2.Germany,
Headquarter Location:USA
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions.

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes on product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Top Ranked Articles about Catalyst Biosciences Inc

Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis
Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
Steven Cohen Sees Value in Nightstar Therapeutics Billionaire investor takes stake in clinical-stage gene therapy company
Guru investor Steven Cohen (Trades, Portfolio), who heads up the multibillion-dollar hedge fund Point72 Asset Management, disclosed he established a 5.2% stake in Nightstar Therapeutics Ltd. (NASDAQ:NITE) on Aug. 6, adding to his holdings in the health care space. Read more...
Catalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Update
Thinking about buying stock in Ameri Holdings, Catalyst Biosciences, Micron, Riot Blockchain Inc or AT&T?
Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis
Steven Cohen Powers Into C&J Energy Services Guru boosts position 170%
Point72 fund manager Steven Cohen (Trades, Portfolio) disclosed on Monday that he increased his C&J Energy Services (NYSE:CJ) holding by 170%. Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.88
CBIO's PB Ratio is ranked higher than
93% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CBIO: 0.88 )
Ranked among companies with meaningful PB Ratio only.
CBIO' s PB Ratio Range Over the Past 10 Years
Min: 0.3  Med: 1.14 Max: 12.53
Current: 0.88
0.3
12.53
PS Ratio 70.43
CBIO's PS Ratio is ranked lower than
79% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBIO: 70.43 )
Ranked among companies with meaningful PS Ratio only.
CBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.49  Med: 9.96 Max: 347.06
Current: 70.43
0.49
347.06
EV-to-EBIT 0.57
CBIO's EV-to-EBIT is ranked higher than
91% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CBIO: 0.57 )
Ranked among companies with meaningful EV-to-EBIT only.
CBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -1557.8  Med: -1.7 Max: 43.3
Current: 0.57
-1557.8
43.3
EV-to-EBITDA 0.57
CBIO's EV-to-EBITDA is ranked higher than
92% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CBIO: 0.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.7  Med: -1.7 Max: 204.9
Current: 0.57
-58.7
204.9
EV-to-Revenue -18.86
CBIO's EV-to-Revenue is ranked lower than
99.99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CBIO: -18.86 )
Ranked among companies with meaningful EV-to-Revenue only.
CBIO' s EV-to-Revenue Range Over the Past 10 Years
Min: -51.2  Med: 6.1 Max: 257.5
Current: -18.86
-51.2
257.5
Current Ratio 56.98
CBIO's Current Ratio is ranked higher than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CBIO: 56.98 )
Ranked among companies with meaningful Current Ratio only.
CBIO' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 6.38 Max: 60.98
Current: 56.98
0.89
60.98
Quick Ratio 56.98
CBIO's Quick Ratio is ranked higher than
99% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CBIO: 56.98 )
Ranked among companies with meaningful Quick Ratio only.
CBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 6.37 Max: 60.98
Current: 56.98
0.89
60.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -145.10
CBIO's 3-Year Average Share Buyback Ratio is ranked lower than
96% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CBIO: -145.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -464.6  Med: -12.5 Max: 12.6
Current: -145.1
-464.6
12.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.91
CBIO's Price-to-Net-Cash is ranked higher than
97% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CBIO: 0.91 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CBIO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.87  Med: 2.13 Max: 17.44
Current: 0.91
0.87
17.44
Price-to-Net-Current-Asset-Value 0.89
CBIO's Price-to-Net-Current-Asset-Value is ranked higher than
97% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CBIO: 0.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.5  Med: 1.73 Max: 15.94
Current: 0.89
0.5
15.94
Price-to-Tangible-Book 0.89
CBIO's Price-to-Tangible-Book is ranked higher than
96% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CBIO: 0.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.49  Med: 1.35 Max: 11.54
Current: 0.89
0.49
11.54
Price-to-Median-PS-Value 7.09
CBIO's Price-to-Median-PS-Value is ranked lower than
95% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CBIO: 7.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.83 Max: 26.36
Current: 7.09
0.07
26.36
Earnings Yield (Greenblatt) % 178.25
CBIO's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CBIO: 178.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1305.1  Med: -14 Max: 56533.7
Current: 178.25
-1305.1
56533.7

More Statistics

Revenue (TTM) (Mil) $0.75
EPS (TTM) $ -3.40
Beta2.91
Volatility149.45%
52-Week Range $4.15 - 37.00
Shares Outstanding (Mil)11.94

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}